Safety Data Sheet



Section 1: Identification

Product identifier

Product Name _ Flurbiprofen Sodium Ophthalmic Solution

Product Code _ NDC 69292-0722-25

Relevant identified uses of the substance or mixture and uses advised against

Recommended use __ Finished Pharmaceutical Product; Flurbiprofen sodium ophthalmic solution is indicated

for the inhibition of intraoperative miosis.

Restrictions on use_ Use in accordance with product literature. Refer to the product insert and/or

prescribing information for restrictions on use and contraindications.

Details of the supplier of the safety data sheet

Manufacturer _ Amici Pharmaceuticals LLC

425 Broadhollow Road Suite 115

Melville, NY 11747 United States

Telephone (General) 631 – 396 - 0111

Emergency telephone number

Manufacturer _ 631 - 396 - 0111

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to consumer use of the product.

Section 2: Hazard Identification

UN GHS

According to: UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

Classification of the substance or mixture

UN GHS Eye Mild Irritation 2B

Label elements

UN GHS

WARNING

Hazard statements May cause eye irritation

Precautionary statements

Prevention: Use personal protective equipment as required.

Wash thoroughly after handling.

Response: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,

if present and easy to do. Continue rinsing.

If eye irritation persists: Get medical advice/attention.

Preparation Date: 20/February/2018

Revision Date:
Page 1 of 9

Format: GHS Language: English (US)

UN GHS

Storage/Disposal: Keep tightly closed. Store at room temperature 15-25°C (59-77°F), to maintain product

integrity. Use before date marked on carton and/or container.

Other hazards

UN GHS No data available

Section 3 - Composition/Information on Ingredients

Substances

 Material does not meet the criteria of a substance according to United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

Mixtures

Eye

		Comp	osition
Chemical Name	Identifiers	%	Classifications According to Regulation/Directive
Citric acid	CAS:77-92-9 EINECS:201-069-1	< 0.1%	UN GHS: Skin Irrit. 2; Eye Irrit. 2A; Acute Tox. Oral 5
Edetate Disodium Dihydrate	CAS:139-33-3 EINECS:205-358-3	< 1%	UN GHS: NDA
Flurbiprofen	CAS:5104-49-4 EINECS:225-827-6	0.03%	UN GHS: NDA
Polyvinyl alcohol	CAS:9002-89-5	1.4%	UN GHS: NDA
Potassium chloride	CAS:7447-40-7 EINECS:231-211-8	< 1%	UN GHS: Skin Irrit. 2; Eye Irrit. 2A; Acute Tox. Oral 5; STOT RE 1
Sodium chloride	CAS:7647-14-5 EINECS:231-598-3	0.1%	UN GHS: Skin Irrit. 2; Eye Irrit. 2A; Acute Tox. Oral 5
Sodium Citrate Dihydrate	CAS:68-04-2 EINECS:200-675-3	1% TO 5%	UN GHS: Eye Irrit. 2A
Thimerosal	CAS:54-64-8 EINECS:200-210-4	0.005%	UN GHS: Skin Irrit. 2; Eye Irrit. 2A
Water	CAS:7732-18-5 EINECS:231-791-2	Balance	UN GHS: Classification criteria not met

Hydrochloric Acid (CAS:7647-01-0, EINECS:231-595-7) and/or Sodium Hydroxide (CAS# 1310-73-2, EINECS: 215-185-5) may be added to adjust the pH.

The exact percentage of composition has been withheld as a trade secret.

Section 4: First-Aid Measures

Description of first aid measures

Inhalation _ _ No specific treatment is necessary since this material is not likely to be hazardous by inhalation. If exposed to excessive levels of mists, remove to fresh air and get medical

attention.

Skin

- No specific treatment is necessary since this material is not likely to be hazardous by contact with the skin or mucous membranes.

 For accidental and non-therapeutic applications, flush eyes with copious amounts of water for at least 15 minutes. Get medical attention if eye irritation persists.

Ingestion - No specific treatment is necessary since this material is not likely to be hazardous by ingestion. If large quantities are accidentally ingested (greater than a tablespoon), get

Preparation Date: 20/February/2018

Revision Date:
Page 2 of 9

Format: GHS Language: English (US)

UN GHS

medical attention immediately.

Most important symptoms and effects, both acute and delayed

No data available

Indication of any immediate medical attention and special treatment needed

Notes to Physician

With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased bleeding due to interference with thrombocyte aggregation.

Other information

Have the product container or label with you when calling a poison control center or doctor, or going for treatment.

Section 5: Fire-Fighting Measures

Extinguishing media

Suitable Extinguishing Media _Water spray, carbon dioxide, dry chemical powder or appropriate foam for surrounding fire.

Unsuitable Extinguishing

Media

No data available

Special hazards arising from the substance or mixture

Unusual Fire and Explosion

Hazards

- None known - product is not flammable or combustible.

Hazardous Combustion

Products

No data available

Advice for firefighters

As in any fire, wear self-contained breathing apparatus and full protective gear to prevent contact with skin and eyes.

Section 6 - Accidental Release Measures

Personal precautions, protective equipment and emergency procedures

Personal Precautions

No special controls or personal protection required under conditions of intended use. In the event of bulk spills, wear suitable protective eyewear, clothing, protective boots and protective gloves. Refer to Section 8.

Emergency Procedures

No emergency procedures are expected to be necessary when used in accordance with product literature.

Environmental precautions

- No data available

Methods and material for containment and cleaning up

Containment/Clean-up Measures

- Contain spilled product. For small spills, add suitable absorbent material. Scoop up and place in an appropriate liquid-tight container equipped with a tight cover for disposal. For large spills, dike spilled material or otherwise contain material to ensure runoff does not reach a waterway. Place spilled material in an appropriate, liquid-tight container equipped with a tight cover for disposal.

Section 7 - Handling and Storage

Precautions for safe handling

Handling

No special handling is required. Refer to Section 8. Use only in accordance with product literature.

Conditions for safe storage, including any incompatibilities

Storage - Keep tightly closed. Store at room temperature 15-25°C (59-77°F), to maintain product

Preparation Date: 20/February/2018 Format: GHS Language: English (US) UN GHS Revision Date: Page 3 of 9

integrity. Use before date marked on carton and/or container.

Section 8 - Exposure Controls/Personal Protection

Control parameters

Exposure Limits/Guidelines

Refer to the occupational exposure limits / guidelines for the individual product components.

Exposure controls

Engineering Measures/Controls Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

Personal Protective Equipment

Respiratory Eye/Face

- No respiratory protection required during normal handling.

Avoid contact with the eye. No special controls or personal protection required under

conditions of intended use. In the event of a bulk spill, appropriate eye protection

should be worn.

Hands - Gloves are not required under normal handling conditions.

Skin/Body No special personal protection required under conditions of intended use. In the event

of a bulk spill, wear appropriate protective clothing.

Environmental Exposure

Controls

No data available

Section 9 - Physical and Chemical Properties

Information on Physical and Chemical Properties

Material Description			
Physical Form	Liquid	Color	Clear Colorless to slightly yellow.
Odor	No odor.	Odor Threshold	Not relevant
General Properties		-	-
Boiling Point	No data available	Melting Point	Not relevant
Decomposition Temperature	Not relevant	рН	6 to 7
Specific Gravity/Relative Density	= 1.016	Water Solubility	Miscible
Viscosity	No data available		
Volatility			•
Vapor Pressure	Not relevant	Vapor Density	Not relevant
Evaporation Rate	No data available		
Flammability		-	-
Flash Point	Not relevant	UEL	Not relevant
LEL	Not relevant	Burning Rate Test	Not relevant
Environmental			
Octanol/Water Partition coefficient	No data available		

Section 10: Stability and Reactivity

Reactivity

No dangerous reactions known.

Chemical stability

Preparation Date: 20/February/2018 Format: GHS Language: English (US) Revision Date: UN GHS

_ Stable under normal temperatures and pressures.

Possibility of hazardous reactions

- No data available

Conditions to avoid

- Extreme heat or cold. Do not freeze.

Incompatible materials

- None.

Hazardous decomposition products

- None expected.

Section 11 - Toxicological Information

Information on toxicological effects

Other Material Information

Toxicological information refers to raw materials only. Concentrations and toxicological effects are substantially reduced in the product.

		Components
Flurbiprofen (0.03%)	5104- 49-4	Acute Toxicity: Ingestion/Oral-Rat LD50 • 117 mg/kg; Behavioral:Ataxia; Gastrointestinal:Hypermotility, diarrhea; Blood:Normocytic anemia
Polyvinyl alcohol (1.4%)	9002- 89-5	Acute Toxicity: Ingestion/Oral-Rat LD50 • 23854 mg/kg; Behavioral:Muscle weakness; Gastrointestinal:Hypermotility, diarrhea; Liver:Other changes
Thimerosal (0.005%)	54-64- 8	Acute Toxicity: Ingestion/Oral-Rat LD50 • 75 mg/kg
Edetate Disodium Dihydrate (< 1%)	139-33- 3	Acute Toxicity: Ingestion/Oral-Rat LD50 • 2 g/kg
Potassium chloride (< 1%)	7447- 40-7	Acute Toxicity: Ingestion/Oral-Rat LD50 • 2600 mg/kg
Citric acid (< 0.1%)	77-92- 9	Acute Toxicity: Ingestion/Oral-Rat LD50 • 3 g/kg
Sodium Citrate Dihydrate (1% TO 5%)	68-04- 2	Acute Toxicity: Intravenous-Mouse LD50 • 170 mg/kg; Behavioral:Convulsions or effect on seizure threshold; Lungs, Thorax, or Respiration:Cyanosis; Gastrointestinal:Changes in structure or function of salivary glands
Sodium chloride (0.1%)	7647- 14-5	Acute Toxicity: Ingestion/Oral-Rat LD50 • 3000 mg/kg

GHS Properties	Classification
Acute toxicity	UN GHS • Classification criteria not met
Aspiration Hazard	UN GHS • Classification criteria not met
Carcinogenicity	UN GHS • Classification criteria not met
Germ Cell Mutagenicity	UN GHS • Classification criteria not met
Skin corrosion/Irritation	UN GHS • Classification criteria not met
Skin sensitization	UN GHS • Classification criteria not met
STOT-RE	UN GHS • Classification criteria not met
STOT-SE	UN GHS • Classification criteria not met

Preparation Date: 20/February/2018

Revision Date: Page 5 of 9 UN GHS

Toxicity for Reproduction	UN GHS • Classification criteria not met
Respiratory sensitization	UN GHS • Classification criteria not met
Serious eye damage/Irritation	UN GHS • Eye Mild Irritation 2B

Potential Health Effects Inhalation

Acute (Immediate) - Under normal conditions of use, no health effects are expected. **Chronic (Delayed)** - Under normal conditions of use, no health effects are expected.

Skin

Acute (Immediate) - Under normal conditions of use, no health effects are expected. **Chronic (Delayed)** - Under normal conditions of use, no health effects are expected.

Acute (Immediate) May cause mild irritation. Transient ocular burning and stinging. With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased bleeding due to interference with thrombocyte aggregation.

Chronic (Delayed) Ingestion

- Under normal conditions of use, no health effects are expected.

Acute (Immediate) **Chronic (Delayed)**

- Under normal conditions of use, no health effects are expected. - Under normal conditions of use, no health effects are expected.

Other

Acute (Immediate) - Under normal conditions of use, no health effects are expected. Chronic (Delayed) - Under normal conditions of use, no health effects are expected.

		Carcinogenic Effects	
	CAS	IARC	NTP
Polyvinyl alcohol	9002-89-5	Group 3-Not Classifiable	Evidence of Carcinogenicity

Reproductive Effects

While the finished product is believed to be safe, some ingredients are suspected of causing cancer. The safety of this product in pregnant women has not been established. Flurbiprofen has been shown to be embryocidal, delay parturition, prolong gestation, reduce weight, and/or slightly retard growth of fetuses when given to rats in daily oral doses of 0.4 mg/kg (approximately 300 times the human daily topical dose) and above.

Section 12 - Ecological Information

Toxicity

- This material has not been tested for environmental effects.

Persistence and degradability

- No data available

Bioaccumulative potential

- No data available

Mobility in Soil

- No data available

Other adverse effects

Section 13 - Disposal Considerations

Preparation Date: 13/May/2015 Revision Date: 13/May/2015 UN GHS Page 6 of 9

Format: GHS Language: English (US)

Waste treatment methods

Product waste

- Waste characterizations and compliance with applicable laws are the responsibility solely of the waste generator.

Packaging waste

Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

Section 14 - Transport Information

	UN number	UN proper shipping name	Transport hazard class (es)	Packing group	Environmental hazards
DOT	NDA	Not regulated	NDA	NDA	NDA
TDG	NDA	Not regulated	NDA	NDA	NDA
IMO/IMDG	NDA	Not regulated	NDA	NDA	NDA
IATA/ICAO	NDA	Not regulated	NDA	NDA	NDA

Special precautions for user

- No data available

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

- No data available

Section 15 - Regulatory Information

Safety, health and environmental regulations/legislation specific for the substance or mixture **SARA Hazard Classifications** - Nodataavailable

		Inver	ntory	
Component	CAS	Canada DSL	EU EINECS	TSCA
Flurbiprofen	5104-49-4	Yes	Yes	No
Edetate Disodium Dihydrate	139-33-3	Yes	Yes	Yes
Citric acid	77-92-9	Yes	Yes	Yes
Thimerosal	54-64-8	Yes	Yes	Yes
Polyvinyl alcohol	9002-89-5	Yes	No	Yes
Potassium chloride	7447-40-7	Yes	Yes	Yes
Sodium chloride	7647-14-5	Yes	Yes	Yes
Sodium Citrate Dihydrate	68-04-2	Yes	Yes	Yes
Water	7732-18-5	Yes	Yes	Yes

Canada

Canada - WHMIS - Classifications of Substances		
Sodium Citrate Dihydrate	68-04-2	Uncontrolled product according to WHMIS classification criteria
Edetate Disodium Dihydrate	139-33-3	Uncontrolled product according to WHMIS classification criteria (including 3.5%)

Preparation Date: 20/February/2018 Format: GHS Language: English (US) Revision Date: 20/February/2018 UN GHS

Thimerosal	54-64-8	Not Listed
Potassium chloride	7447-40-7	Uncontrolled product according to WHMIS classification criteria (including 23.8%)
Citric acid	77-92-9	E (including 40%) Uncontrolled product
Sodium chloride	7647-14-5	according to WHMIS classification criteria
Flurbiprofen	5104-49-4	Not Listed
• Water	7732-18-5	Uncontrolled product according to WHMIS classification criteria
Polyvinyl alcohol	9002-89-5	Not Listed
Canada - WHMIS - Ingredient Disclosure List		
Sodium Citrate Dihydrate	68-04-2	Not Listed
Edetate Disodium Dihydrate	139-33-3	Not Listed
Thimerosal	54-64-8	0.1 %
Potassium chloride	7447-40-7	Not Listed
Citric acid	77-92-9	1 %
Sodium chloride	7647-14-5	Not Listed
Flurbiprofen	5104-49-4	Not Listed
Water	7732-18-5	Not Listed
Polyvinyl alcohol	9002-89-5	Not Listed

United States

Quantities	
68-04-2	Not Listed
139-33-3	Not Listed
54-64-8	Not Listed
7447-40-7	Not Listed
77-92-9	Not Listed
7647-14-5	Not Listed
5104-49-4	Not Listed
7732-18-5	Not Listed
9002-89-5	Not Listed
	139-33-3 54-64-8 7447-40-7 77-92-9 7647-14-5 5104-49-4 7732-18-5

United States - California

J.S California - Proposition 65 - Carcinogens List Sodium Citrate Dihydrate	68-04-2	Not Listed	
•			
Edetate Disodium Dihydrate	139-33-3	Not Listed	
Thimerosal	54-64-8	Not Listed	
Potassium chloride	7447-40-7	Not Listed	
Citric acid	77-92-9	Not Listed	
Sodium chloride	7647-14-5	Not Listed	
Flurbiprofen	5104-49-4	Not Listed	
• Water	7732-18-5	Not Listed	
Polyvinyl alcohol	9002-89-5	Not Listed	
U.S California - Proposition 65 - Developmental Toxicity			
Sodium Citrate Dihydrate	68-04-2	Not Listed	

Preparation Date: 20/February/2018

Revision Date: 20/February/2018

UN GHS

UN GHS

	139-33-3	Not Listed
Thimerosal	54-64-8	Not Listed
Potassium chloride	7447-40-7	Not Listed
Citric acid	77-92-9	Not Listed
Sodium chloride	7647-14-5	Not Listed
Flurbiprofen	5104-49-4	developmental toxicity, initial date 8/20/99
Water	7732-18-5	Not Listed
Polyvinyl alcohol	9002-89-5	Not Listed
U.S California - Proposition 65 - Reproductive Toxicity - Female		
Sodium Citrate Dihydrate	68-04-2	Not Listed
Edetate Disodium Dihydrate	139-33-3	Not Listed
Thimerosal	54-64-8	Not Listed
Potassium chloride	7447-40-7	Not Listed
Citric acid	77-92-9	Not Listed
Sodium chloride	7647-14-5	Not Listed
Flurbiprofen	5104-49-4	female reproductive toxicity, initial date 8/20/99
Water	7732-18-5	Not Listed
Polyvinyl alcohol	9002-89-5	Not Listed
U.S California - Proposition 65 - Reproductive Toxicity - Male		
Sodium Citrate Dihydrate	68-04-2	Not Listed
Edetate Disodium Dihydrate	139-33-3	Not Listed
Thimerosal	54-64-8	Not Listed
Potassium chloride	7447-40-7	Not Listed
Citric acid	77-92-9	Not Listed
Sodium chloride	7647-14-5	Not Listed
Flurbiprofen	5104-49-4	Not Listed
Water	7732-18-5	Not Listed
Polyvinyl alcohol	9002-89-5	Not Listed

Section 16 - Other Information

Last Revision Date Preparation Date Disclaimer/Statement of Liability

_20/February/2018

20/February/2018

_ To the best of our knowledge, the information contained herein is accurate. However, neither Amici Pharmaceuticals LLC nor any of its subsidiaries assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. NO WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY, FITNESS OR OTHERWISE IS MADE. In no event shall Amici Pharmaceuticals LLC or any of its subsidiaries be liable for any special, incidental or consequential damages.

Preparation Date: 20/February/2018 Format: GHS Language: English (US) Revision Date: 20/February/2018 Page 9 of 9